• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在完全缓解 1 期的 AML 患者中,行清髓性异基因造血干细胞移植后,总感染和细菌感染增加。

Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

机构信息

Division of Hematology/Oncology/Cell Therapy, Rush University, Chicago, IL.

Center for International Blood and Marrow Transplant Research, Department of Medicine, and.

出版信息

Blood Adv. 2019 Sep 10;3(17):2525-2536. doi: 10.1182/bloodadvances.2019000226.

DOI:10.1182/bloodadvances.2019000226
PMID:31471322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6737406/
Abstract

Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT-comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range, <1-99 days]; RIC/NMA, 21 days [range, <1-100 days]; < .001). Patients receiving MAC were more likely to experience at least 1 bacterial infection by day 100 (MAC, 46% [95% confidence interval (CI), 43-49]; RIC/NMA, 37% [95% CI, 34-41]; = .0004), whereas at least a single viral infection was more prevalent in the RIC/NMA cohort (MAC, 34% [95% CI, 31-37]; RIC/NMA, 39% [95% CI, 36-42]; = .046). MAC remained a risk factor for bacterial infections in multivariable analysis (relative risk, 1.44; 95% CI, 1.23-1.67; < .0001). Moreover, the rate of any infection per patient-days at risk in the first 100 days (infection density) after alloHCT was greater for the MAC cohort (1.21; 95% CI, 1.11-1.32; < .0001). RIC/NMA was associated with reduced infections, especially bacterial infections, in the first 100 days after alloHCT.

摘要

推测,与清髓性预处理(MAC)方案相比,异基因造血细胞移植(alloHCT)中的减低强度/非清髓性预处理(RIC/NMA)可导致感染减少;然而,现有证据有限。在这项国际血液和骨髓移植研究中心的研究中,评估了 1755 例处于完全缓解期的初治急性髓性白血病(AML)且年龄≥40 岁的患者在 T 细胞补充 alloHCT 后 100 天内发生的感染。与接受 MAC(n=978)的患者相比,接受 RIC/NMA(n=777)的患者年龄更大且移植时间更新;然而,两组在卡氏功能状态评分、HCT 合并症指数和细胞遗传学风险方面相似。1045 例(59.5%)患者发生 1 次或更多次感染(MAC:595 [61%];RIC/NMA:450 [58%]; =.21),中位至首次感染时间在 MAC 预处理后更早(MAC:15 天[范围:<1-99 天];RIC/NMA:21 天[范围:<1-100 天]; <.001)。在第 100 天,MAC 患者更有可能至少发生 1 次细菌感染(MAC:46%[95%置信区间(CI):43-49];RIC/NMA:37%[95% CI:34-41]; =.0004),而 RIC/NMA 组中至少发生 1 次病毒感染更常见(MAC:34%[95% CI:31-37];RIC/NMA:39%[95% CI:36-42]; =.046)。多变量分析中 MAC 仍然是细菌感染的危险因素(相对风险,1.44;95% CI:1.23-1.67; <.0001)。此外,alloHCT 后第 100 天(感染密度)内每位患者的风险感染率(患者-天)在 MAC 队列中更高(1.21;95% CI:1.11-1.32; <.0001)。RIC/NMA 与 alloHCT 后前 100 天内感染减少相关,尤其是细菌感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e02e/6737406/dd711828e5bd/advancesADV2019000226absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e02e/6737406/dd711828e5bd/advancesADV2019000226absf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e02e/6737406/dd711828e5bd/advancesADV2019000226absf1.jpg

相似文献

1
Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.在完全缓解 1 期的 AML 患者中,行清髓性异基因造血干细胞移植后,总感染和细菌感染增加。
Blood Adv. 2019 Sep 10;3(17):2525-2536. doi: 10.1182/bloodadvances.2019000226.
2
Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.可测量残留疾病、调理方案强度和年龄可预测首次缓解的急性髓系白血病患者接受异基因造血细胞移植的结果:欧洲血液和骨髓移植学会急性白血病工作组对 2292 例患者的注册分析。
Am J Hematol. 2018 Sep;93(9):1142-1152. doi: 10.1002/ajh.25211. Epub 2018 Aug 15.
3
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中,减低剂量预处理方案与清髓性预处理方案的比较结果:单中心经验
Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.
4
Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.清髓性而非减低剂量预处理可克服急性髓系白血病中白血病流式细胞术证据的负面影响。
Biol Blood Marrow Transplant. 2016 Apr;22(4):669-675. doi: 10.1016/j.bbmt.2015.10.024. Epub 2015 Nov 10.
5
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.强度调节的困境:清髓性调节如何改善异基因造血细胞移植的结局。
Biol Blood Marrow Transplant. 2019 Mar;25(3):606-612. doi: 10.1016/j.bbmt.2018.09.012. Epub 2018 Sep 19.
6
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.与减低强度预处理相比,采用清髓性预处理进行 HLA 配型相合的同胞异基因干细胞移植治疗急性髓系白血病后的长期生存及晚期事件:代表欧洲血液与骨髓移植组急性白血病工作组的报告
J Hematol Oncol. 2016 Nov 8;9(1):118. doi: 10.1186/s13045-016-0347-1.
7
Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.脐带血移植后预处理方案强度对急性髓系白血病疗效的影响。
Biol Blood Marrow Transplant. 2011 Sep;17(9):1327-34. doi: 10.1016/j.bbmt.2011.01.007. Epub 2011 Jan 11.
8
Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.基于静脉注射白消安或全身照射的清髓性预处理方案对急性髓系白血病缓解期并接受异基因造血细胞移植的儿科患者的结局比较:来自日本造血细胞移植学会的报告
Biol Blood Marrow Transplant. 2015 Dec;21(12):2141-2147. doi: 10.1016/j.bbmt.2015.08.011. Epub 2015 Aug 10.
9
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.急性髓系白血病和骨髓增生异常综合征的清髓性与减低强度造血细胞移植
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
10
Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant.预处理方案强度对接受异基因移植的外周 T 细胞淋巴瘤、间变大细胞淋巴瘤和血管免疫母细胞 T 细胞淋巴瘤患者结局的影响。
Br J Haematol. 2022 Apr;197(2):212-222. doi: 10.1111/bjh.18052. Epub 2022 Feb 2.

引用本文的文献

1
Use of Immunoglobulin Replacement Therapy in Clinical Practice: A Review.免疫球蛋白替代疗法在临床实践中的应用:综述
J Immunother Precis Oncol. 2025 Jan 10;8(1):34-46. doi: 10.36401/JIPO-24-7. eCollection 2025 Feb.
2
Post-transplantation cyclophosphamide is associated with increased bacterial infections.移植后环磷酰胺与细菌感染增加有关。
Bone Marrow Transplant. 2024 Jan;59(1):76-84. doi: 10.1038/s41409-023-02131-z. Epub 2023 Oct 31.
3
A calibrated Bayesian method for the stratified proportional hazards model with missing covariates.

本文引用的文献

1
Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation.细菌血流感染(BSI),特别是移植后 BSI,与异基因造血细胞移植后死亡率增加相关。
Bone Marrow Transplant. 2019 Aug;54(8):1254-1265. doi: 10.1038/s41409-018-0401-4. Epub 2018 Dec 13.
2
Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring.巨细胞病毒再激活与异基因造血干细胞移植后晚期侵袭性真菌感染风险增加相关:病毒载量监测时代的多中心研究。
Biol Blood Marrow Transplant. 2017 Nov;23(11):1961-1967. doi: 10.1016/j.bbmt.2017.07.025. Epub 2017 Aug 7.
3
一种带有缺失协变量的分层比例风险模型的校准贝叶斯方法。
Lifetime Data Anal. 2022 Apr;28(2):169-193. doi: 10.1007/s10985-021-09542-4. Epub 2022 Jan 16.
4
Prevention and management of carbapenem-resistant Enterobacteriaceae in haematopoietic cell transplantation.造血干细胞移植中耐碳青霉烯类肠杆菌科细菌的预防与管理
Ther Adv Infect Dis. 2021 Oct 27;8:20499361211053480. doi: 10.1177/20499361211053480. eCollection 2021 Jan-Dec.
5
Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study.严重急性移植物抗宿主病增加异基因造血细胞移植后血流感染和死亡率:日本移植登记研究。
Bone Marrow Transplant. 2021 Sep;56(9):2125-2136. doi: 10.1038/s41409-021-01291-0. Epub 2021 Apr 19.
6
Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend "when and for whom" in 2021?异基因造血细胞移植预处理中的剂量强度:2021年我们能否推荐“何时以及针对何人”?
Haematologica. 2021 Jul 1;106(7):1794-1804. doi: 10.3324/haematol.2020.268839.
7
Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.急性髓系白血病:从生物学通过研发和临床前治疗到临床实践
Front Oncol. 2020 Dec 9;10:599933. doi: 10.3389/fonc.2020.599933. eCollection 2020.
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.急性髓系白血病和骨髓增生异常综合征的清髓性与减低强度造血细胞移植
J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13.
4
Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.既往侵袭性真菌感染并非血液系统恶性肿瘤患者接受异基因造血干细胞移植的禁忌证:一项国际骨髓移植登记处(CIBMTR)的研究
Bone Marrow Transplant. 2017 Feb;52(2):270-278. doi: 10.1038/bmt.2016.259. Epub 2016 Dec 19.
5
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation.接受替代供者造血细胞移植的急性白血病患者的感染率
Biol Blood Marrow Transplant. 2016 Sep;22(9):1636-1645. doi: 10.1016/j.bbmt.2016.06.012. Epub 2016 Jun 22.
6
Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia.清髓性而非减低剂量预处理可克服急性髓系白血病中白血病流式细胞术证据的负面影响。
Biol Blood Marrow Transplant. 2016 Apr;22(4):669-675. doi: 10.1016/j.bbmt.2015.10.024. Epub 2015 Nov 10.
7
Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.异基因造血干细胞移植后非曲霉菌霉菌感染的危险因素及影响:一项CIBMTR感染与免疫重建分析
Bone Marrow Transplant. 2016 Feb;51(2):277-82. doi: 10.1038/bmt.2015.263. Epub 2015 Nov 2.
8
Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years.70岁及以上急性髓系白血病/骨髓增生异常综合征患者的脐带血移植结果
Biol Blood Marrow Transplant. 2016 Feb;22(2):390-393. doi: 10.1016/j.bbmt.2015.09.020. Epub 2015 Sep 28.
9
Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.脐带血和匹配同胞供者异基因造血细胞移植后急性和慢性移植物抗宿主病的危险因素
Biol Blood Marrow Transplant. 2016 Jan;22(1):134-40. doi: 10.1016/j.bbmt.2015.09.008. Epub 2015 Sep 11.
10
Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis.急性髓系白血病和急性淋巴细胞白血病患者异基因造血干细胞移植中减低强度与清髓性预处理方案的比较:一项荟萃分析
Stem Cells Dev. 2014 Nov 1;23(21):2535-52. doi: 10.1089/scd.2014.0123. Epub 2014 Sep 17.